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bjectives We sought to determine whether an obesity paradox exists in the contemporary era of
ercutaneous coronary intervention (PCI) and to explore potential clinical factors that might contribute.
ackground Previous studies have suggested that overweight and obese patients might have bet-
er outcomes after PCI than patients with a normal or low body mass index (BMI); however this
obesity paradox” remains poorly understood.
ethods We evaluated 4,762 patients undergoing PCI between April 1, 2004 and September 30,
007, enrolled in the MIG (Melbourne Intervention Group) registry. Patients were classiﬁed as under-
eight, normal, overweight, class I obese, and class II to III obese, BMI 20, 20 to 25, 25.1 to 30,
0.1 to 35, and 35 kg/m2, respectively. We compared in-hospital, 30-day, and 12-month outcomes.
esults As BMI increased from 20 to 35 kg/m2, there was a statistically signiﬁcant, linear reduc-
ion in 12-month major adverse cardiac events (MACE) (21.4% to 11.9%, p  0.008) and mortality
7.6% to 2.0%, p  0.001). Obesity was, with multivariate analysis, an independent predictor of re-
uced 12-month MACE and showed a trend for reduced 12-month mortality. At 12 months, obese
atients had higher use of aspirin, clopidogrel, beta-blockers, renin-angiotensin system blockers and
tatins.
onclusions Compared with normal-weight individuals, overweight and obese patients had lower
n-hospital and 12-month MACE and mortality rates after PCI. Moreover, obese patients had a higher
ate of guideline-based medication use at 12 months, which might in part explain the obesity para-
ox seen after PCI. (J Am Coll Cardiol Intv 2010;3:660–8) © 2010 by the American College of
ardiology Foundation
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661besity has been described as a worldwide epidemic, and its
revalence is increasing at an alarming rate. In 2005, 1.6
illion adults were classified as overweight and at least 400
illion were obese (1). This is expected to rise to 2.3 billion
verweight and 700 million obese adults by 2015. The
dverse health consequences associated with obesity are
ell-documented, including coronary artery disease (CAD),
troke, heart failure, hypertension, and diabetes (2). Obesity
as also been linked with higher rates of malignancy and
verall mortality (3,4). Yet, increasingly, studies also suggest
hat obesity might also have a protective role in some chronic
iseases once they are established, including CAD (5,6), heart
ailure (7), end-stage renal failure (8), and stroke (9).
Recent studies, including a meta-analysis, have demon-
trated an “obesity paradox” after percutaneous coronary
ntervention (PCI), whereby overweight and obese patients
eem to have better outcomes compared with normal weight
ndividuals (10–15). Similar findings have also been dem-
nstrated after coronary artery bypass graft (CABG) surgery
16). Few studies, however, have attempted to explain
hy this paradox exists. One observation is that obese
atients are more likely to receive guideline-based medical
herapy during hospital admission and at discharge (6,17).
lternatively, it is possible that “underweight” individuals,
t the other extreme, might have increased adverse event
ates. We sought to confirm that an obesity paradox exists in
he modern era of PCI and to determine whether obese
atients are more likely to remain on optimal medical
herapy at 12 months after procedure.
ethods
tudy population and data collection. We analyzed 4,762
atients undergoing PCI procedures between April 1, 2004
nd September 30, 2007, enrolled in the MIG (Melbourne
ntervention Group) registry. The MIG registry is a volun-
ary collaborative PCI registry comprising 7 major public
nd private hospitals in Victoria, Australia. Registry design
nd methods of data collection have been described previ-
usly (18). Data are prospectively collected at the time of
CI, with a case report form that includes standardized
efinitions for all fields. The study protocol has been
pproved by the ethics committee at each participating
ospital, and “opt-out” informed consent was obtained from
ll patients.
The registry is coordinated by the Centre for Cardiovas-
ular Research and Education in Therapeutics at Monash
niversity in Melbourne, Australia. Case record forms for
he collection of registry data have been developed with
eleform, version 9 (Cardiff, Vista, California). Completed
orms are faxed to the data center, verified on receipt, and
lectronically uploaded into the central database. An inde-
endent audit of data collection was conducted at all sites by
n investigator not affiliated with that institution. Fifteen cerifiable fields from 5% of all patients enrolled from each
ite were randomly selected and audited. Overall data
ccuracy was determined to be 97%, which compares
avorably with other large registries (19).
Body mass index (BMI) was calculated by dividing the
eight in kilograms by the square of the height in meters.
atients were classified as underweight (BMI 20 kg/m2,
 131), normal weight (BMI 20 to 25 kg/m2, n 1,189),
verweight (BMI 25.1 to 30 kg/m2, n  2,016), class I
bese (BMI 30.1 to 35 kg/m2, n 1,021), and class II to III
bese (BMI 35 kg/m2, n  405), in line with the World
ealth Organization classification system (1). Height and
eight values were recorded at the time of PCI. In-hospital
omplications were recorded at the time of hospital dis-
harge. Thirty-day and 12-month clinical outcomes and
edication use were ascertained
y telephone interview, and
edical records were reviewed
o substantiate adverse events.
linical outcomes and deﬁnitions.
n-hospital outcomes included
ll-cause mortality, cardiac death,
eriprocedural myocardial infarc-
ion (MI) (defined as new MI
uring or after PCI with at least 1
nstance of elevation of creatine
inase/creatine kinase myocardial
and 3 the upper limit of
ormal and/or evolutionary ST-
egment elevation, development
f new Q waves in 2 or more
ontiguous electrocardiography
eads, or new left bundle branch
lock pattern); MACE (compris-
ng death, MI, and urgent revas-
ularization); congestive cardiac
ailure (CCF); arrhythmia (de-
ned as a new or acute recurrence
f an atrial or ventricular arrhyth-
ia requiring treatment or a new high-level atrioventricular
lock); emergency PCI; emergency CABG; new renal impair-
ent (defined as an increase of creatinine to 0.20 mmol/l
nd 2 the baseline creatinine level or a new requirement for
ialysis); stroke; and bleeding (defined as requiring a transfu-
ion and/or prolonged hospital stay and/or causing a drop in
emoglobin 3.0 g/dl). Thirty-day and 12-month clinical
utcomes included all-cause mortality, cardiac death, MI,
arget lesion revascularization (TLR) (defined as revasculariza-
ion within 5 mm of a previously treated lesion); target vessel
evascularization (TVR) (defined as revascularization of a
reviously treated coronary artery), and MACE (comprising
eath, MI, and TVR). All patients included in this study had
Abbreviations
and Acronyms
BMI  body mass index
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CCF  congestive cardiac
failure
DES  drug-eluting stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PVD  peripheral vascular
disease
RAS  renin-angiotensin
system
TLR  target lesion
revascularization
TVR  target vessel
revascularizationompleted 12-month follow-up or had known MACE. This
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662epresents 93.5% of the total cohort (n  5,072), and rates of
ollow-up were similar in each BMI group.
tatistical analysis. Continuous variables were expressed as
ean  SD and compared with analysis of variance.
ategorical variables were expressed as percentages and
ompared with linear association and Pearson chi-square
ests as appropriate. Two-sided p values of 0.05 were
onsidered statistically significant. Multivariate logistic re-
ression analysis was used to determine independent pre-
ictors of 12-month MACE and mortality. Twenty-eight
ariables were considered, including age 75 years, BMI,
ex, diabetes, hypertension, dyslipidemia, smoking, family
istory of CAD, renal failure, existing CCF, peripheral
ascular disease (PVD), cerebrovascular disease, chronic
ung disease, obstructive sleep apnea, previous MI, previous
CI, previous CABG, out-of-hospital cardiac arrest, cardi-
Table 1. Baseline Clinical Characteristics According to BMI
Variable
<20 kg/m2
(n  131)
20–25 kg/m2
(n  1,189)
Age (yrs) 68.8 12.6 67.4 11.8
Female 52 (39.7) 318 (26.8)
Diabetes 18 (13.7) 189 (15.9)
Insulin-requiring diabetes 5 (3.8) 44 (3.7)
Hypertension 76 (58.0) 696 (58.6)
Dyslipidemia 76 (58.9) 808 (68.5)
Family history of CAD 45 (34.9) 457 (39.7)
Current smoker 35 (26.9) 275 (23.4)
Current or past smoking 87 (66.9) 733 (62.4)
Baseline creatinine (mmol/l) 0.105 0.10 0.099 0.12
Renal failure† 9 (6.9) 51 (4.3)
Previous MI 45 (34.9) 348 (29.3)
Existing CCF‡ 11 (8.4) 49 (4.1)
Cerebrovascular disease 8 (6.1) 88 (7.4)
Peripheral vascular disease 10 (7.6) 90 (7.6)
Chronic lung disease 29 (22.3) 129 (10.9)
Obstructive sleep apnea 1 (0.8) 23 (2.0)
Previous PCI 40 (30.5) 289 (24.3)
Previous CABG 13 (9.9) 110 (9.3)
Clinical presentation/indication
STEMI 33 (25.2) 299 (25.2)
NSTEMI 33 (25.2) 260 (21.9)
Unstable angina pectoris 17 (13.0) 181 (15.3)
Stable angina 34 (26.0) 369 (31.1)
Atypical angina 5 (3.8) 33 (2.8)
No angina 9 (6.9) 43 (3.6)
NYHA functional class I to II 87 (78.4) 766 (82.3)
NYHA functional class III to IV 24 (21.6) 165 (17.7)
New CCF§ 13 (9.9) 71 (6.0)
Cardiogenic shock/IABP 4 (3.1) 35 (2.9)
Data are n (%) or mean SD unless otherwise stated. *p value calculated with Pearson chi-square t
(CCF), at least 2 weeks before presentation. §New CCF, within 2 weeks of presentation.
BMIbodymass index; CABG coronary arterybypassgraft; CAD coronary arterydisease; IABP
infarction; NYHA New York Heart Association functional class; PCI percutaneous coronary integenic shock/intra-aortic balloon pump, New York Heart hssociation functional class, ST-segment-elevation MI,
merican College of Cardiology and American Heart
ssociation type B2 and C lesions, procedures involving the
eft anterior descending or left main coronary artery, bypass
raft lesion, small stent size 2.5 mm, long stent length
20 mm, use of glycoprotein IIb/IIIa inhibitors, and use
f drug-eluting stents (DES). All variables with a value of
0.1 in the univariate model were included in the
ultivariate analysis.
esults
tudy population. Baseline patient characteristics are listed
Table 1). Of 4,762 patients, 3,442 (72%) were overweight or
bese. There were more men than women in all BMI groups;
5.1–30 kg/m2
(n  2,016)
30.1–35 kg/m2
(n  1,021)
>35 kg/m2
(n  405) p Value
64.7 11.7 63.0 11.6 59.7 10.7 0.036
423 (21.0) 240 (23.5) 158 (39.0) 0.001*
450 (22.3) 271 (26.5) 164 (40.6) 0.001
89 (4.4) 53 (5.2) 44 (10.9) 0.001
1,245 (61.9) 699 (68.6) 322 (79.5) 0.001
1,435 (71.7) 749 (73.6) 311 (77.6) 0.001
876 (44.5) 458 (46.4) 194 (49.1) 0.001
395 (19.9) 219 (21.8) 99 (24.6) 0.714
1,329 (67.0) 688 (68.5) 280 (69.5) 0.003
0.097 0.08 0.093 0.04 0.089 0.06 0.001
58 (2.9) 29 (2.8) 13 (3.2) 0.024
568 (28.2) 315 (30.9) 111 (27.5) 0.669
69 (3.4) 36 (3.5) 20 (5.0) 0.446
87 (4.3) 52 (5.1) 30 (7.4) 0.384
141 (7.0) 56 (5.5) 21 (5.2) 0.023
184 (9.2) 113 (11.1) 55 (13.8) 0.841
63 (3.1) 59 (5.8) 50 (12.4) 0.001
494 (24.5) 263 (25.8) 101 (24.9) 0.967
185 (9.2) 90 (8.8) 32 (7.9) 0.388
440 (21.9) 200 (19.6) 84 (20.7) 0.003
491 (24.4) 280 (27.5) 108 (26.7) 0.007
290 (14.4) 132 (13.0) 52 (12.8) 0.154
650 (32.4) 345 (33.9) 141 (34.8) 0.031
52 (2.6) 31 (3.0) 10 (2.5)
86 (4.3) 31 (3.0) 10 (2.5)
1,283 (83.4) 641 (81.7) 264 (79.3) 0.478
256 (16.6) 144 (18.3) 69 (20.7) 0.478
78 (3.9) 43 (4.2) 17 (4.2) 0.006
45 (2.2) 21 (2.1) 5 (1.2) 0.035
nal failure defined as baseline serum creatinine0.20 mmol/l. ‡Existing congestive cardiac failure
-aortic balloonpump;MImyocardial infarction;NSTEMInon–ST-segment elevationmyocardial
; STEMI ST-segment elevation myocardial infarction.2
est. †Re
 intraowever, the percentage of female patients was higher at the
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663xtremes of BMI. Obese patients had a significantly higher
revalence of diabetes, hypertension, dyslipidemia, obstructive
leep apnea, current or past cigarette smoking, and family
istory of CAD. Notably, 40% of class II to III obese patients
ad diabetes. Underweight and normal weight patients were
ignificantly older and more likely to have renal failure and
VD. Chronic lung disease, existing CCF, previous MI and
revious PCI were numerically higher in underweight patients;
owever, there was no statistically significant linear trend
cross the BMI groups. In a separate analysis, BMI20 kg/m2
as compared with BMI 20 kg/m2, with a statistically
ignificant higher prevalence of chronic lung disease (p 
.001) and CCF (p  0.018) in underweight patients. Acute
oronary syndromes (ACS) were the most common indication
or PCI in all groups and comprised approximately two-thirds
f all procedures. Compared with obese patients, underweight
nd normal weight patients were more likely to present with
T-segment-elevation myocardial infarction, new CCF, and
Table 2. Lesion Characteristics, Procedural Details, and Acute Medication
Variable
<20 kg/m2
(n  131)
20–25 kg/m2
(n  1,189)
Lesion characteristics
Multivessel disease 69 (63.3) 591 (62.5)
Left main lesion 2 (1.2) 16 (1.1)
Proximal LAD lesion 29 (17.0) 211 (14.3)
Graft lesion 4 (2.3) 43 (2.9)
ACC/AHA type B2 or C lesion 89 (52.0) 681 (46.1)
Procedural details
No stent 11 (8.4) 75 (6.3)
Bare-metal stent 66 (50.4) 565 (47.5)
Drug-eluting stent 54 (41.2) 549 (46.2)
Femoral access 129 (98.5) 1,135 (95.5)
Radial access 1 (0.8) 47 (4.0)
Brachial access 1 (0.8) 7 (0.6)
Closure device used 17 (13.2) 163 (14.0)
Pre-stenosis (%) 86.29 11.3 86.2 12.1
Post-stenosis (%) 7.1 20.3 4.8 17.4
Stent total length (mm) 17.76 7.86 18.13 9.18
Stent diameter (mm) 2.88 0.45 2.89 0.46
Maximum balloon size (mm) 2.93 0.49 2.95 0.50
Unsuccessful procedure 6 (4.6) 54 (4.6)
In-hospital medication use
Glycoprotein IIb/IIIa inhibitors 36 (27.5) 324 (27.2)
Unfractionated heparin 124 (94.7) 1,143 (96.1)
Low molecular weight heparin 27 (20.6) 251 (21.2)
Clopidogrel 126 (96.2) 1,165 (98.2)
72 h before PCI 41 (31.3) 390 (32.9)
72 h before PCI 27 (20.6) 184 (15.5)
During/after PCI 58 (44.3) 591 (49.8)
Data are n (%) or mean SD unless otherwise stated.
ACC/AHA American College of Cardiology and American Heart Association; LAD left anterioardiogenic shock/intra-aortic balloon pump. The prevalence Tf New York Heart Association functional class III to IV
ymptoms at presentation were similar.
esion characteristics and procedural details. High-risk cor-
nary lesions, multivessel disease, the use of DES, final
ngiographic result, and procedural success were similar
Table 2). There was a statistically significant difference in
tent diameter and maximum balloon size used in class II to
II obese patients. Use of glycoprotein IIb/IIIa inhibitors,
lopidogrel, and unfractionated heparin were similar; how-
ver, low molecular weight heparin use was higher in class II
o III obese patients.
linical outcomes. In-hospital, 30-day, and 12-month out-
omes are shown (Tables 3 and 4, Figs. 1 and 2). Compared
ith normal weight patients, class II to III obese patients
ad significantly fewer in-hospital cardiac complications,
ncluding periprocedural MI, arrhythmias, CCF, and
ACE. In-hospital mortality was lowest in class II to III
bese patients and there was a trend to lower cardiac death.
25.1–30kg/m2
(n  2,016)
30.1–35 kg/m2
(n  1,021)
>35 kg/m2
(n  405) p Value
969 (58.1) 519 (60.6) 211 (58.3) 0.210
22 (0.9) 7 (0.6) 3 (0.6) 0.116
361 (14.5) 174 (14.0) 75 (15.1) 0.829
81 (3.2) 35 (2.8) 8 (1.6) 0.322
1,227 (49.2) 578 (46.4) 240 (48.4) 0.966
106 (5.3) 67 (6.6) 17 (4.2) 0.518
960 (47.6) 475 (46.5) 207 (51.1) 0.518
950 (47.1) 479 (46.9) 181 (44.7) 0.518
1,914 (94.9) 964 (94.4) 384 (94.8) 0.182
98 (4.9) 49 (4.8) 20 (4.9) 0.182
4 (0.2) 8 (0.8) 1 (0.2) 0.182
318 (16.3) 158 (16.0) 63 (16.0) 0.249
86.5 11.8 86.7 11.4 86.0 12.3 0.815
4.9 18.2 5.2 18.9 4.3 15.4 0.450
18.23 8.42 18.31 7.99 18.41 8.17 0.919
2.93 0.47 2.95 0.49 2.99 0.50 0.001
2.98 0.53 3.01 0.55 3.06 0.57 0.001
90 (4.5) 45 (4.4) 11 (2.7) 0.249
564 (28.0) 269 (26.3) 112 (27.7) 0.808
1,938 (96.1) 980 (96.1) 392 (96.8) 0.495
490 (24.4) 266 (26.2) 116 (28.6) 0.001
1,975 (98.2) 999 (98.1) 398 (98.5) 0.358
652 (32.4) 325 (31.9) 140 (34.7)
355 (17.7) 199 (19.5) 72 (17.8)
968 (48.1) 475 (46.7) 186 (46.0)
ding artery; other abbreviations as in Table 1.Usehe in-hospital incidence of stent thrombosis, stroke,
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664leeding, and vascular complications were not significantly
ifferent between groups. There was no significant differ-
nce in MI, TLR, TVR, MACE, or mortality at 30 days.
s BMI increased from 20 to 35 kg/m2, there was a
tatistically significant, linear reduction in 12-month
ACE (21.4% to 11.9%, p 0.008) and mortality (7.6% to
.0%, p  0.001). Twelve-month cardiac mortality demon-
Table 3. In-Hospital Complications
Complication
<20 kg/m2
(n  131)
20–25 kg/m2
(n  1,189)
Arrhythmia 8 (6.1) 58 (4.9)
CCF 4 (3.1) 35 (2.9)
Periprocedural MI 2 (1.6) 26 (2.2)
New renal impairment 2 (1.5) 14 (1.2)
Stroke 0 (0) 3 (0.3)
Stent thrombosis* 0 (0) 1 (0.7)
Coronary dissection 0 (0) 4 (0.3)
Perforation 0 (0) 4 (0.3)
Tamponade 1 (0.8) 1 (0.1)
Emergency PCI 0 (0) 10 (0.9)
Unplanned CABG 1 (0.8) 8 (0.7)
Bleeding 5 (3.8) 27 (2.3)
Pseudoaneurysm 1 (0.8) 3 (0.3)
Data are n (%). *Total cohort 565 patients.
Abbreviations as in Table 1.
Table 4. Mortality and Cardiac Complications
Complication
<20.0 kg/m2
(n  131)
20–25 kg/m2
(n  1,189)
25.
(n
In-hospital
MACE 6 (4.6) 53 (4.5)
Mortality
All-cause 3 (2.3) 14 (1.2)
Cardiac 3 (2.3) 10 (0.8)
30 Days
MI 2 (1.5) 37 (3.1)
TLR 1 (0.8) 23 (1.9)
TVR 1 (0.8) 30 (2.5)
MACE 6 (4.6) 72 (6.1)
Mortality
All-cause 3 (2.3) 19 (1.6)
Cardiac 3 (2.3) 13 (1.1)
12 Months
MI 16 (12.2) 58 (4.9)
TLR 6 (4.6) 61 (5.1)
TVR 13 (9.9) 91 (7.7)
MACE 28 (21.4) 165 (13.9)
Mortality
All-cause 10 (7.6) 48 (4.0)
Cardiac 4 (3.1) 23 (1.9)
Data are n (%).MACEmajor adverse cardiac events, including target vessel revascularization (TVR), myocardial infarcttrated a similar trend but did not reach statistical signifi-
ance. Rates of 12-month MI, TLR, and TVR were not
ignificantly different.
redictors of outcome. Independent predictors of 12-
onth MACE and mortality are listed (Tables 5 and 6).
ith multivariate analysis, where BMI was entered as a
ontinuous variable, BMI was an independent predictor of
–30 g/m2
2,016)
30.1–35 kg/m2
(n  1,021)
>35 kg/m2
(n  405) p Value
9 (4.4) 29 (2.8) 8 (2.0) 0.001
9 (1.9) 11 (1.1) 7 (1.7) 0.005
7 (1.9) 12 (1.2) 3 (0.8) 0.030
0 (1.0) 9 (0.9) 1 (0.2) 0.097
4 (0.2) 1 (0.1) 0 (0) 0.327
5 (2.0) 3 (2.8) 1 (2.2) 0.220
7 (0.3) 1 (0.1) 0 (0) 0.229
0 (0.5) 2 (0.2) 0 (0) 0.388
4 (0.2) 1 (0.1) 0 (0) 0.309
8 (0.9) 8 (0.8) 4 (1.0) 0.638
2 (0.6) 9 (0.9) 2 (0.5) 0.932
1 (2.0) 22 (2.2) 8 (2.0) 0.447
5 (0.2) 6 (0.6) 1 (0.2) 0.653
g/m2
16)
30.1–35 kg/m2
(n  1,021)
>35.0 kg/m2
(n  405) p Value
0) 28 (2.7) 8 (2.0) 0.005
9) 6 (0.6) 1 (0.2) 0.013
9) 6 (0.6) 1 (0.2) 0.059
9) 20 (2.0) 6 (1.5) 0.071
2) 22 (2.2) 8 (2.0) 0.587
4) 27 (2.6) 10 (2.5) 0.578
6) 47 (4.6) 15 (3.7) 0.066
1) 11 (1.1) 4 (1.0) 0.141
0) 9 (0.9) 3 (0.7) 0.233
6) 40 (3.9) 21 (5.2) 0.057
8) 46 (4.5) 25 (6.2) 0.761
8) 75 (7.3) 35 (8.6) 0.996
.5) 115 (11.3) 48 (11.9) 0.008
9) 22 (2.2) 8 (2.0) 0.001
7) 15 (1.5) 5 (1.2) 0.14325.1
(n 
8
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252 (12
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35 (1.ion (MI), and death; TLR target lesion revascularization.
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6652-month MACE (odds ratio: 0.980 per unit increase
g/m2 of BMI, 95% confidence interval: 0.961 to 0.999,
 0.035) with a trend for reduced 12-month mortality
odds ratio: 0.961 per unit increase kg/m2 of BMI, confi-
ence interval: 0.922 to 1.001, p  0.056).
0-day and 12-month medication use. Medication use at 30
ays and 12 months are shown (Table 7). At 30-day
ollow-up, the use of renin-angiotensin system (RAS)
lockers was lowest in underweight patients and highest in
lass II to III obese patients (69.7% vs. 83.6%, p  0.001),
nd there was a trend to higher beta-blocker use in obese
atients. At 12-month follow-up, there was a statistically
ignificant difference in the use of all guideline-
Figure 1. Kaplan-Meier Graph Illustrating Survival Curves for BMI Cohort
at 12 Months
Overweight and obese patients had a lower death rate up to 12 months
after percutaneous coronary intervention. BMI  body mass index (kg/m2).
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Figure 2. Kaplan-Meier Graph Illustrating MACE-Free Survival at
12 Months
Underweight patients had a higher major adverse cardiac event (MACE)
rate up to 12 months after percutaneous coronary intervention, and obese
2patients had the lowest event rate. BMI  body mass index (kg/m ).ecommended medications. Compared with normal weight
atients, class II to III obese patients were more likely to be
aking aspirin (92.7% vs. 90.1%, p  0.035), clopidogrel
66.1% vs. 59.5%, p  0.037), beta-blockers (65.8% vs.
6.0%, p  0.001), RAS-blockers (81.1% vs. 72.7%,
0.001), and statins (90.7% vs. 89.8%, p  0.044).
iscussion
n this study of PCI outcomes and medication use according
o BMI, obese patients had a higher prevalence of tradi-
ional cardiovascular risk factors compared with nonobese
atients, yet the latter group were older and more likely to
ave renal failure and PVD. Class II to III obese patients
ad significantly lower in-hospital cardiac complications
nd mortality and significantly lower 12-month MACE and
ortality. After multivariate analysis, increasing BMI con-
erred a protective effect for both 12-month MACE and
ortality. This finding is counterintuitive, and yet it has
een consistently reported in several earlier studies (10–15).
n important new finding of our study is that obese patients
Table 5. Independent Predictors of 12-Month MACE
Variable OR 95% CI p Value
Age (per yr) 1.012 1.004–1.021 0.004
BMI* (per 1 kg/m2) 0.980 0.961–0.999 0.035
Shock/IABP 3.689 2.391–5.692 0.001
Renal failure 2.138 1.456–3.140 0.001
LAD lesion 1.553 1.253–1.925 0.001
Small vessels (2.5 mm)† 1.527 1.255–1.858 0.001
Diabetes 1.459 1.184–1.799 0.001
Glycoprotein IIb/IIIa 1.495 1.204–1.857 0.001
ACC/AHA B2/C lesions 1.383 1.149–1.666 0.001
Previous MI 1.281 1.052–1.559 0.014
Hypertension 1.236 1.005–1.520 0.045
DES 0.549 0.452–0.667 0.001
*BMI calculated as a continuous variable. †Mean stent diameter.
CI confidence interval; DES drug-eluting stent; OR odds ratio; other abbreviations as in
Tables 1, 2, and 4.
Table 6. Independent Predictors of 12-Month Mortality
Variable OR 95% CI p Value
Age (per yr) 1.056 1.036–1.077 0.001
BMI* (per 1 kg/m2) 0.961 0.922–1.001 0.056
Shock/IABP 11.155 6.439–19.326 0.001
Renal failure 5.269 3.127–8.881 0.001
Chronic lung disease 2.212 1.424–3.437 0.001
STEMI 2.198 1.378–3.505 0.001
CCF† 1.907 1.049–3.465 0.034
PVD 1.860 1.105–3.133 0.020
Diabetes 1.620 1.082–2.424 0.019
*BMI calculated as a continuous variable. †Existing CCF, at least 2 weeks before presentation.PVD peripheral vascular disease; other abbreviations as in Tables 1 and 5.
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666ere more likely to be receiving guideline-recommended
edical therapy at 12 months after PCI.
edical therapy. Optimal medical therapy improves mor-
idity and mortality in CAD and remains the cornerstone of
reatment (20–22). The COURAGE (Clinical Outcomes
tilizing Revascularization and Aggressive Drug Evalua-
ion) trial (20) was a timely reminder, that advances in
echnology have not supplanted the need for careful atten-
ion to proven drug-therapies and risk factor modification.
aber et al. (21) examined the effect of using multiple
vidence-based classes of cardiovascular medications (anti-
latelet agents, beta-blockers, RAS-blockers, and lipid-
owering therapy) on long-term outcomes after PCI. De-
pite having a higher risk profile at the time of PCI, patients
reated with 3 or 4 of the aforementioned medications had
lower mortality rate at 36 months. A Canadian registry
22) demonstrated similar findings in ACS patients.
Studies to date have reported on short-term differences in
ardiac medications after PCI according to BMI. Steinberg
t al. (17) found that increased BMI was associated with an
ncreased use of guideline-based medical therapy both
n-hospital and at discharge in 130,139 patients hospitalized
or CAD. Likewise, Diercks et al. (6) demonstrated that
bese patients with ACS were more likely to undergo
ppropriate invasive procedures and to be discharged on
ipid-lowing therapy and clopidogrel. Importantly, we dem-
nstrated that this increased use of optimal medical therapy
s most dramatic at 12 months, coinciding with the im-
rovement in MACE and mortality.
Differences in baseline characteristics, such as diabetes
ellitus, hypertension, and dyslipidemia might partly ac-
ount for this finding. It could be argued, however, that all
Table 7. Medication Use at Follow-Up
Medication
<20.0 kg/m2
(n  131)
20–25 kg/m2
(n  1,189)
25
(
30 days
Aspirin 116 (95.9) 1,078 (97.5)
Clopidogrel 116 (95.9) 1,030 (93.5)
Beta-blocker 76 (65.0) 716 (65.5)
RAS-blocker 83 (69.7) 792 (72.5)
Statin 102 (85.0) 1,009 (92.1)
Warfarin 8 (6.6) 53 (4.8)
12 months
Aspirin 95 (84.8) 943 (90.1)
Clopidogrel 71 (63.4) 618 (59.5)
Beta-blocker 61 (57.0) 580 (56.0)
RAS-blocker 78 (72.2) 751 (72.7)
Statin 89 (81.7) 933 (89.8)
Warfarin 2 (1.9) 51 (4.9)
Data are n (%).
RAS renin-angiotensin system.atients with CAD should be treated with long-term teta-blockers, RAS-blockers, and statins (23). Further-
ore, increased use of antiplatelet therapy is not explained
y either differences in baseline characteristics or the use of
ES. The importance of neurohormonal blockade in obese
atients with CAD was supported by Kennedy et al. (24)
ho found that BMI was associated with an increased
ortality risk among obese patients who were not receiving
eta- or RAS-blockade. Nonpharmacological measures
uch as smoking cessation, cardiac rehabilitation, and di-
tary counseling have also been shown to be higher in
verweight and obese patients (6).
besity and cardiovascular risk. The use of BMI to estimate
ardiovascular risk has been challenged in recent years (25).
ecause BMI does not discriminate adipose tissue content,
igher BMI values might in some cases simply reflect
reater lean body mass composition. Recently, a large study
y Gelber et al. (26) comparing BMI, waist/hip ratio,
aist/height ratio, and waist circumference found waist/
eight ratio showed the strongest association with incident
ardiovascular disease. The differences were small, how-
ver, and the authors concluded they were unlikely to be
linically meaningful. Body mass index has been exten-
ively studied, provides the “most useful population-level
easure” of obesity because it is the same for both sexes
1), and the World Health Organization endorses its use
s a measure of obesity by using BMI to define and
lassify obesity.
Whether obesity is a predictor of cardiac events indepen-
ent of other risk factors remains controversial. The
NTERHEART study (Effect of potentially modifiable risk
actors associated with myocardial infarction in 52 coun-
ries) (27) found that BMI was not an independent predic-
kg/m2
016)
30.1–35 kg/m2
(n  1,021)
>35.0 kg/m2
(n  405) p Value
7.0) 922 (96.8) 371 (97.4) 0.901
4.3) 894 (94.0) 357 (93.7) 0.948
7.6) 656 (70.6) 253 (66.8) 0.086
6.3) 725 (77.8) 317 (83.6) 0.001
1.8) 868 (92.5) 352 (92.6) 0.127
.3) 52 (5.5) 16 (4.2) 0.597
2.0) 831 (91.2) 341 (92.7) 0.035
2.4) 570 (63.1) 242 (66.1) 0.037
0.7) 551 (61.5) 240 (65.8) 0.001
5.2) 720 (80.0) 296 (81.1) 0.001
1.6) 825 (91.5) 333 (90.7) 0.044
.7) 47 (5.2) 14 (3.8) 0.879.1–30
n  2,
1,841 (9
1,779 (9
1,265 (6
1,427 (7
1,726 (9
81 (4
1,662 (9
1,118 (6
1,075 (6
1,332 (7
1,637 (9
84 (4or of first MI after multivariate adjustment. Perhaps
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667urrent obesity measures are largely surrogate markers of
isk factors that are found more commonly in untreated
bese patients, such as an adverse lipid profile. Therefore,
argeted treatment of these risk factors after PCI might help
xplain why the reverse effect is seen, where obesity is seen as
protective.”
ovel mechanisms. Novel theories to explain the obesity
aradox after PCI have included the suggestion that obese
atients have “larger vessels” (28). We found that coronary
tent diameter (used as a surrogate for vessel size) progres-
ively increased with BMI. In addition, after multivariate
nalysis, small vessel size was an independent predictor of
2-month MACE. An English study (29) also found that
id–left anterior descending coronary artery diameter pos-
tively correlated with BMI in cardiac surgical patients and
hat patients with larger vessel size had lower in-hospital
ortality. Underweight patients in our study had the
mallest vessel size and the highest in-hospital and 12-
onth MACE and mortality.
Adipose tissue is increasingly being recognized as an
ctive endocrine organ; however, the effects of “adipokines”
n coronary arteries and atherosclerosis are incompletely
nderstood. Uretsky et al. (5) postulated that increased
roduction of soluble tumor necrosis factor receptors by
dipose cells in obese subjects might have a cardioprotective
ffect in patients with heart failure. Leptin, an adipokine
hat is increased in obesity, has previously been implicated
s an independent risk factor for CAD (30). However, a
ecent study has shown that low serum leptin levels correlate
ith angiographically determined CAD (31). Furthermore,
omin et al. (32) demonstrated that leptin is an
ndothelial-independent vasodilator. Clearly, additional
tudy is warranted to elucidate whether these adipokines can
elp explain the obesity paradox.
tudy limitations. This study is a retrospective observational
nalysis; however, all the data were collected prospectively in
previously described multicenter registry. Although the
verall number of patients included in this study was
ubstantial, we excluded patients with missing height and/or
eight data—which is a potential source of selection bias.
he BMI was assessed at the time of PCI, which does not
ecessarily reflect BMI at 12 months. Our follow-up was 12
onths; however, a longer period is warranted to assess the
mpact of obesity on long-term mortality after PCI and to
urther evaluate the effect of medication differences on
ubsequent morbidity and mortality.
onclusions
his study suggests that overweight and obese individuals
re at lowest risk of in-hospital complications and 12-
onth MACE and mortality after PCI. Although many
heories have been proposed to explain this paradox, differ-
nces in medication use is certainly an important, potentiallyodifiable factor. To improve our understanding of the
besity paradox and its mechanisms, a prospective study is
equired, including additional measures of obesity and
iomarkers, measured both at baseline and during follow-
p. Furthermore, we should investigate why patients with a
ow or normal BMI are at higher risk of morbidity and
ortality after PCI and whether this risk can be ameliorated
hrough targeted medical therapy.
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